Summary
A protein-bound polysaccharide from mycelia ofCoriolus versicolor PS-K, clinically used as an immunomodulator, has been shown to restore the decreased cellular immune response and to exhibit host-mediated antitumor activity. In this experiment, PS-K was found to increase serum complement level in guinea pig and in human without malignancy, when hemolytic assay of complement was performed using sensitized sheep erythrocytes for the classical pathway activity and unsensitized rabbit erythrocytes for the alternative pathway activity. Assay of complement components revealed increase in C3 level in guinea pig, but no significant changes in Clq, C4, C3, properdin, C3 activator, and C\(\bar 1\)-inhibitor in human, while C5 and C9 were depressed. Conversion ofβ1C toβ1A was observed in the 7th day's plasma of these patients by crossed immunoelectrophoresis. Biosynthesis of guinea pig C3 was accelerated by administration of PS-K, but that of C4 was not affected. These evidences suggested that PS-K might potentiate immune response of the host by elevating serum complement level, in addition to the activation of the complement system.
Similar content being viewed by others
References
Barnes EW, Farmer A, Penhale WJ, Irvine WJ, Roscoe P, Horne NW (1975) Phytohemagglutinin-induced lymphocyte transformation in newly presenting patients with primary carcinoma of the lung. Cancer 36:187–193
Bessis M (1949) The use of replacement transfusion in diseases other than hemolytic disease of the new born. Blood 4:324–337
Chihara G, Maeda YY, Hamuro J, Sasaki T, Fukuoka F (1969) Inhibition of mouse sarcoma-180 by polysaccharide fromLentinus edodes (Berk) sing. Nature (Lond) 222:687–688
Goldstein IM, Bral M, Osler AG, Weissmann G (1973) Lysosomal enzyme release from human leukocytes: Mediation by the alternative pathway of complement activation. J Immunol 111:33–37
Haba S, Hamaoka T, Takatsu K, Kitagawa M (1978) Selective suppression of T-cell activity in tumor-bearing mice and its improvement by lentinan, a potent anti-tumor polysaccharide. Int J Cancer 18:93–104
Henson EM (1971) The immunologic release of constituents from neutrophile leukocytes. I. The role of antibody and complement on non-phagocytable surfaces or phagocytable particles. J Immunol 107:1535–1546
Hersh EM, Oppenheim JJ (1965) Impaired in vitro lymphocyte transformation in Hodgkin's disease. New Engl J Med 273:1006–1012
Kassel RL, Old LJ, Carswell EA, Fiore NC, Hardy WJ Jr (1973) Serum-mediated leukemia cell destruction in AKR mice. J Exp Med 138:925–938
Kimura I, Ohnoshi T, Yasuhara S, Sugiyama M, Urabe Y, Fujii M, Machida K (1976) Immunochemotherapy in human lung cancer using the streptococcal agent OK-432. Cancer 37:2201–2203
Kondo M, Kagawa K, Kato H, Yoshikawa T, Nishigaki I, Nakanishi K, Nakai T, Kashima K, Hosokawa K, Tsunoda F, Kodama M (1975) Phytohemagglutinin skin test in aged individuals. Preliminary report. J Kyoto Pref Univ Med 84:77–82
Kondo M, Kato H, Yokoe N, Matsumura N, Hotta T, Masuda M (1978) Activation of the complement system by immunostimulants, BCG, OK-432 (Picibanil), and PS-K (Krestin) in vitro. Gann 69:699–702
Laurell CB (1965) Antigen-antibody crossed electrophoresis. Anal Biochem 10:358–361
Mathe G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F (1969) Active immunotherapy for acute lymphoblastic leukemia. Lancet I:697–699
Mayer MM (1965) Mechanism of hemolysis by complement. Ciba Foundation Symposium on Complement. Churchill, London, pp 4–32
McKenzie D, Colsky J, Hetrick DL (1967) Complement reactivity of cancer patients: Measurements by immune hemolysis and immune adherence. Cancer Res 27:2386–2394
Nelson RA Jr (1953) The immune adherence phenomenon. Science 118:733–737
Nishioka K (1967) Complement and tumor immunology. Adv Cancer Res 14:231–291
Nishioka K, Kawamura K, Hirayama T, Kawashima T, Shimada K, Kogure M (1976) The complement system in tumor immunity: Significance of elevated levels of complement in tumor-bearing hosts. Ann NY Acad Sci 276:303–315
Nomoto K, Yoshikumi C, Matsunaga K, Fujii T, Takeya K (1975) Restoration of antibody-forming capacities by PS-K in tumor-bearing mice. Gann 66:365–374
Ohno R, Imai K, Yokomaku S, Yamada K (1975) Antitumor effect of protein-bound polysaccharide preparation, PS-K, against 3-methylcholanthrene-induced fibrosarcoma in C57BL/6 mice. Gann 66:679–681
Ohno R, Yokomaku S, Wakayama K, Sugiura S, Yamada K (1976) Blastoid transformation of human lymphocytes cultured with protein-bound polysaccharide preparation, PS-K, in vitro. Gann 67:713–716
Okamoto H, Minami M, Shoin S (1966) Experimental anti-cancer studies Part XXXI. On the streptococcal preparation having patent anti-cancer activity. Jpn J Exp Med 36:175–186
Orita K, Miwa H, Shinoda K, Tanaka S (1973) Suppressed blastformation of lymphocyte in cancer-bearing patients, with special reference to the cancers of the digestive tract. Acta Med Okayama 27:37–41
Pepys MB (1974) Role of complement in induction of antibody production in vivo. J Exp Med 140:126–145
Pepys MB, Butterworth AE (1974) Inhibition by C3 fragments of C3-dependent rosette formation and antigen-induced lymphocyte transformation. Clin Exp Immunol 18:273–282
Perlmann P, Hölm G (1969) Cytotoxic effect of lymphoid cells in vitro. Adv Immunol 11:117–193
Pfordte K, Ponsold W (1969) The tumor-inhibiting effect of properdin. Neoplasma 16:609–612
Platts-Mills TAE, Ishizaka K (1974) Activation of the alternate pathway of human complement by rabbit cells. J Immunol 113:348–358
Renoux G, Renoux M (1972) Levamisole inhibits and cures a solid malignant tumour and its pulmonary metastases in mice. Nature New Biol 240:217–218
Schorlemmer HU, Allison AC (1976) Effect of activated complement components on enzyme secretion by macrophages. Immunology 31:781–788
Sljivic VS, Watson SR (1977) The adjuvant effect ofCorynebacterium pavum: T-cell dependence of macrophage activation. J Exp Med 145:45–57
Tokunaga T, Kataoka T, Nakamura RM, Yamamoto S, Akagawa KS (1978) Mode of action of BCG. Gann monograph on cancer research, no 21. Japan Scientific Societies Press, Tokyo, pp 59–72
Tripodi D, Parks LC, Brugmans J (1973) Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. New Engl J Med 289:354–357
Tsukagoshi S, Ohashi F (1974) Protein-bound polysaccharide preparation PS-K, effective against mouse sarcoma-180 and rat ascites hepatoma AH-13 by oral use. Gann 65:557–558
Verhaegen H, DeCock W, DeCree J, Verbruggen F (1976) Increase of serum complement levels in cancer patients with progressing tumors. Cancer 38:1608–1613
Whittaker MG, Rees K, Clark CG (1971) Reduced lymphocyte transformation in breast cancer. Lancet I:892–893
Woodruff MFA, Boak JL (1966) Inhibitory effect of injection ofCorynebacterium pavum on the growth of tumor transplants in isogenic hosts. Br J Cancer 20:345–355
Yokoe N, Kato H, Takemura S, Yoshikawa T, Kondo M, Hosokawa K, Kodama M (1979) Effect of long-term administration of OK-432 (Picibanil), PS-K (Krestin) and levamisole on immune responses in aged subjects without malignancy. Jpn J Clin Oncol 9:209–214
Yoshida TO, Ito Y (1968) Studies on serum complement level in rabbits bearing tumors of Shope papilloma-carcinoma complex. Immunology 14:879–887
Zarco RM, Flores E, Rodriguez F (1964) Serum complement levels in human cancer. J Philipp Med Assoc 40:839–846
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kato, H., Yokoe, N., Takemura, S. et al. Effect of a protein-bound polysaccharide PS-K on the complement system. Res. Exp. Med. 182, 85–94 (1983). https://doi.org/10.1007/BF01851114
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01851114